Who we are
MirZyme is built by a team of committed and experienced individuals working at the forefront of medical research and business.
About MirZyme
Founded in Birmingham in 2016 and located at Innovation Birmingham Campus, MirZyme Therapeutics is on a global mission to make preeclampsia history. Our value proposition is to save lives, reduce healthcare costs and promote healthy longevity by preventing molecular damage before it starts in utero.
The company is the U.K.’s leading Femtech in Biotech and is developing end-to-end solutions for problems in pregnancy. The founder and CEO is Professor Asif Ahmed, who also founded Aston Medical School. He is a world-renowned entrepreneurial scientist who discovered two pathways to prevent the life-threatening disease preeclampsia.
MirZyme was awarded an Innovation Passport to by the Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of preeclampsia, which will fast-track the development of the first ever orally available treatment to prevent the disease.
Management Team
Chairman and CEO
Asif Ahmed is the founder of MirZyme and a world-renowned British scientist who discovered two protective pathways that can be used to predict, prevent and treat preeclampsia.
Dr May Rezai
Chief Operations Officer
May Rezai obtained her PhD in 2021 and has been working with MirZyme from its inception. She is also the Chair of a UK-wide community based charity.
Mr Sean Power
Business Development Director
Sean Power has extensive experience in financial services, commercial and leisure development, MedTech, and experience in building stakeholder engagement across national health services.
Mr Mike Vousden
Financial Director
Mike Vousden has been a chartered accountant for over 25 years. He is responsible for all the financial aspects of the company.
Dr Faraz Ahmed
Clinical Director of Diagnostics
Faraz Ahmed is an NHS doctor in emergency medicine with prior experience in general and vascular surgery. He has a background in Biochemistry and is the clinical lead for MirZyme's diagnostic assets and their implementation.
Non Executive Directors
Dr Malcolm Barratt-Johnson
Non-Executive
Malcolm Barratt-Johnson is a Physician Scientist and the past president of the Royal Society of Medicine (Pharmaceutical Medicine). He is a lead medical assessor for MHRA and EMA. Malcolm is the MD of PharmaMedic Consultancy Limited.
Mr Sami Ahmad
Non-Executive
Sami Ahmad is CFO of Trecora Resources, a public NYSE-listed (TREC) leading
company in chemicals based in Houston, Texas. Sami has an MBA in finance from the University of Chicago.
Non-Executive
Julia Elizabeth King, Baroness Brown of Cambridge, DBE FREng FRS is a British
engineer and crossbench member of the House of Lords. She was a managing director at Rolls Royce and a member of the governing board of the European Institute of Innovation and Technology.
Dr Wenda Ramma
Non-Executive
Wenda Ramma has a Ph.D. in Vascular Biology and an Executive MBA from the UCLA. Wenda is the Medical Science Liason (Cardiovascular) at Bristol-Myers Squibb. At Amgen Wenda supported the launch of Repatha and other cardiovascular products.
Scientific Advisory Board
Prof Stephen Smith
Chairman
Professor Stephen K. Smith was the first to identify soluble Flt-1 in human placenta and is the former Dean of Medicine at Imperial College & CEO of Imperial College Healthcare.
Dr Swati Agrawal
Member
Dr Swati Agrawal is a maternal fetal medicine doctor in Toronto and has focused her research on preeclampsia.
Dr Allyah Abbas-Hanif
Member
Allyah Abbas-Hanif is an experienced pharmaceutical physician with more than a decade of proficiency in taking drugs from concept to global markets. She is trained in cardiology with an interest in maternal health.